All In Biotech

Drug Trial Radar · NCT05168839

Intraoperative Indocyanine Green Fluorescence Angiography in Colorectal Surgery to Prevent Anastomotic Leakage

Intraoperative Indocyanine Green Fluorescence Angiography in Colorectal Surgery to Prevent Anastomotic Leakage: a Single-blind Phase III Multicenter Randomized Controlled Trial (Intergroup FRENCH-GRECCAR Trial)

Last checked: Nov 19, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 1,010 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

1,010

Planned (sponsor's estimate)

Start

Sep 26, 2022

Primary completion

Oct 31, 2025

Study completion Oct 31, 2025

Sponsor

Lead sponsor
Centre Hospitalier Universitaire de BesanconAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 23, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Colorectal cancer (CRC) is the fourth most commonly diagnosed cancer in the world and the third in France. Its incidence is steadily rising in developing nations. Anastomotic leak (AL) is a major problem in colorectal surgery affecting at least 7% of patients operated on for left colonic cancer. It is the most feared complication after colorectal anastomosis, associated with mortality, prolonged hospitalization, impaired health related quality of life (HRQoL) and increased health care costs. Intraoperative fluorescence angiography (IOFA) with indocyanine green (ICG) may help preventing AL. Available studies on the effects of IOFA with ICG are heterogeneous and randomized controlled trial are scarce. Our aim is to demonstrate that IOFA with ICG could lead to a reduction of AL rate after left-sided or low anterior resection with anastomosis for CRC. The FLUOCOL-1 study is the first national, multicenter, single blind, randomized, 2-arm, phase III superiority clinical trial. The primary endpoint is the occurrence of an AL 90 days post-operation. AL is defined as any anastomotic dehiscence with leakage into the pelvic cavity diagnosed upon imaging or at surgical exploration or any isolated pelvic organ-space infection with no evidence of fistula as defined by the International Study Group of Rectal Cancer. The study population will be made of adult patients with left-sided or high rectal cancer scheduled to undergo elective left colectomy or high rectal resection (by open, laparoscopy or robotic surgery) and with expected stapled or hand-sewn intraperitoneal anastomosis. The exclusion criteria are mainly an emergent surgery; rectal cancer requiring total mesorectal excision and anastomosis expected below the peritoneal reflection; CRC requiring total or subtotal colectomy; CRC requiring transverse colectomy; recurrent CRC and locally advanced colorectal cancer requiring multi-visceral excision. A total of 1010 patients will be necessary (39 patients in each centre during 36 months). An interim analysis for efficacy and futility is scheduled when half of the participants will have been recruited. In case of positive results favoring IOFA, this study would define the use of IOFA as a standard of care in colorectal surgery. At the patient level, a significantly lower rate of AL will reduce hospital stay and stoma rate, and will ensure improved postoperative recovery, faster return to normal activity and better long-term oncologic outcomes.

Conditions

  • Colorectal Cancer

Interventions

  • FLUO+ : Intraoperative fluorescence angiography (IOFA) with indocyanine green (ICG).Drug

    In the experimental arm (FLUO+), at least one 0.1mg/kg Infracyanine® bolus will be injected intravenously by the anesthesiologist. The detection of indocyanine green in the proximal colon segment will be done open or intracorporeally using a dedicated infrared camera. A surgical film describing the injection technique and fluorescence detection will be presented during the study set-up visits. An additional injection is allowed at the surgeon's discretion if necessary (change of anastomosis site). The time from injection to indocyanine green detection and any adverse events will be recorded.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Anastomotic leakage 90 days after surgeryTime frame: 90 days after surgery

Locations

32 sites in 1 country. Site status is shown where the registry gives one.

  • Centre Hospitalier Universitaire Amiens-Picardie

    Amiens, France · Recruiting

  • CH Annecy

    Annecy, France · Recruiting

  • Centre Hospitalier Universitaire de Besançon

    Besançon, France · Recruiting

  • Centre Hospitalier Bourgoin-Jallieu

    Bourgoin, France · Recruiting

  • University Hospital of Dijon

    Dijon, France · Recruiting

  • Centre Georges François Leclerc

    Dijon, France · Recruiting

  • Centre Hospitalier Universitaire de Grenoble

    La Tronche, France · Recruiting

  • Centre Hospitalier Universitaire de Lille

    Lille, France · Recruiting

  • Centre lyonnais de chirurgie digestive

    Lyon, France · Recruiting

  • Centre Hospitalier Lyon-Sud

    Lyon, France · Recruiting

  • Hôpiatl Européen

    Marseille, France · Recruiting

  • Hôpital La Timone

    Marseille, France · Recruiting

  • Institut Paoli Calmettes

    Marseille, France · Not yet recruiting

  • Hôpital Nord AP-HM

    Marseille, France · Recruiting

  • Hôpital St Joseph Marseille

    Marseille, France · Recruiting

  • CHU de Nancy

    Nancy, France · Recruiting

  • Hôpital Saint Louis

    Paris, France · Recruiting

  • Hôpital Saint Antoine

    Paris, France · Recruiting

  • Hôpital Cochin

    Paris, France · Recruiting

  • Hôpital Bicêtre

    Paris, France · Recruiting

  • Hôpital Européen Georges Pompidou

    Paris, France · Recruiting

  • Centre Hospitalier de Pontoise

    Pontoise, France · Recruiting

  • Hôpital Robert Debré

    Reims, France · Recruiting

  • Ch Pontchaillou

    Rennes, France · Recruiting

  • Centre Hospitalier Universitaire de Rouen

    Rouen, France · Recruiting

  • Santé Atlantique

    Saint-Herblain, France · Recruiting

  • Centre Hospitalier Universitaire de Strasbourg

    Strasbourg, France · Not yet recruiting

  • CHU de Toulouse

    Toulouse, France · Recruiting

  • Clinique TIVOLI

    Toulouse, France · Recruiting

  • Centre Hospitalier de Tours

    Tours, France · Recruiting

  • Institut cancérologie de Lorraine

    Vandœuvre-lès-Nancy, France · Recruiting

  • Gustave Roussy

    Villejuif, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.